Top image

Sydney Catalyst: Embedding Research in Cancer Healthcare (EnRICH)

RESEARCH TYPE
T1,T2,T3
PROGRAM
Flagship 1 EnRICH
TAGS
    Epidemiology and health services research
    Implementation research
    Knowledge translation
    Lung cancer
STATUS
In Progress

EnRICH

 

The EnRICH program is a prospective clinical cohort of 1000 patients with lung cancer, which aims to better define, treat and care for patients in Sydney Catalyst member hospitals, and to provide infrastructure for translational cancer research. The program is capturing diagnostic tumour specimens and serial blood samples for molecular and biomarker studies, with matched demographic, clinical and outcome data to map current patterns of care for the diagnosis and treatment of lung cancer, benchmarked against quality indicators. Patient reported outcomes are being collected to assess patient and carer perceptions of care, unmet needs and quality of life to identify opportunities for improving services and patient/carer morbidity.

Patient recruitment commenced in June 2017.

Linked sub-studies:

  • Procoagulant activity (Centenary Institute)
  • Molecular Basis for Intervention During Lung Cancer Evolution (MOBILE) (Garvan Institute)
  • Rapid Autopsy Program in Lung Carcinoma (The Kinghorn Cancer Centre/Garvan Institute)
  • Palliative care-focused collection of biospecimens from patients with life-limiting lung cancer (St Vincent's Hospital Campus)
  • EnRICH/Lung Foundation Australia co-funded PhD Scholarship in Lung Cancer 'Predicting platinum sensitivity in lung cancer' (Garvan Institute)

We are always keen to hear about your ideas for EnRICH sub-studies, so please get in touch: enrich@ctc.usyd.edu.au   

Sponsored by:

  • CINSW TCRC 
  • Sydney Local Health District 
  • St Vincent's Health Sydney

Research Team and Collaborators

Select Publications/Presentations:

Update to Members 1: April 2017 Edition of Sydney Catalyst Newsletter

Update to Members 2: July 2017 Edition of Sydney Catalyst Newsletter

Update to Members 3: October 2017 Edition of Sydney Catalyst Newsletter

Update to Members 4: March 2018 Edition of Sydney Catalyst Newsletter

Update to Members 5: June 2018 Edition of Sydney Catalyst Newsletter

Update to Members 6: September 2018 Edition of Sydney Catalyst Newsletter

 

You might also be interested in...

  • T2,T3
    Amelia Smit: How should genomics be incorporated into Australian healthcare to improve cancer prevention and screening in the population?
    The translation of genomics has great potential to benefit cancer prevention and screening strategies in the Australian population. There is a lack of research evidence on the behavioural, psy...
      Genetics/genomics
      Clinical Trials
      Skin cancer
      Prevention and Early Detection
  • T1
    Ashleigh Morgan: From mice to men: biomarker driven classification of pancreatic cancer to define novel targetable molecular subtypes
    Due to the extremely poor prognosis of pancreatic cancer, and current therapies only being marginally effective, there is an urgent need to develop novel therapeutic strategies. This study aim...
      Biomarkers
      Personalised medicine
      New therapies and diagnostics
  • T1
    Ben Kong: Towards a therapeutic vaccination for glioblastoma multiforme
    The ultimate objective of Ben's research is to create an effective dendritic cell based vaccine for glioblastoma multiforme by exploiting knowledge of DC biology to find the optimum combinatio...
      Dendritic cell
      Immunotherapy
  • T2,T3
    Brooke Nickel: Examination of how different terminologies for early stage cancer or precancerous conditions affect patients' psychological outcomes and decision making regarding treatment
    Changing terminology for low risk, screen detected cancers, has been recommended by several expert groups including the National Institute of Health and the National Cancer Institute in the US but...
      Psychosocial
  • T2,T3
    Cherry Koh & team: Relook Laparoscopy for Peritoneal Surface Disease (ReLaPSed) Trial
    Pilot and Seed Funding Awarded: CIA: Cherry Koh Member Group: Royal Prince Alfred Hospital Year and Duration: 2018 for 15 months Amount: $50,000
      Colorectal cancer
  • T2,T3
    Cindy Tan & team: Body composition changes in cancer patients during chemotherapy
    Chemotherapy dosing is generally determined by a patient's height and weight. This does not account for their body composition and can be inaccurate, particularly in people who are obese or un...
      Personalised medicine
      New therapies and diagnostics
      Colorectal cancer
  • T1
    CINSW RIGs and REGs
    The CINSW Research Equipment and Infrastructure Grants Program is directed to providing substantial funding for key research platforms, core equipment and capacities to enhance the cancer rese...
      Research Equipment
      Research Infrastructure
      CINSW
  • T1
    Claire Vennin: Preclinical targeting of the extracellular matrix to improve chemotherapy and reduce metastasis in patient-stratified models of pancreatic cancer using innovative imaging technologies
    A major challenge in cancer research is to understand and counteract mechanisms of drug resistance. This project will (1) shed light on the role of the ECM in chemoresistance and (2) guide the...
      Biomarkers
      New therapies and diagnostics
  • T2,T3
    Daniel Steffens & team: Feasibility and acceptability of pre-operative exercise to improve patient outcomes after major cancer surgery: A pilot randomised controlled trial
    Promoting physical activity in the pre-operative period appears promising to improve functional capacity and facilitate post-operative recovery. This pilot study will establish the feasibility...
      Clinical Trials
      Exercise
  • T2,T3
    David Barnes and Team: Lung Cancer Demonstration Project
    Cancer Australia engaged four demonstration sites (in four States) to conduct projects that would address five principles of breast practice lung cancer care. Sydney Local Health District part...
      Implementation research
      Lung cancer
      MDT
  • T1
    David Croucher: Mapping and manipulating therapeutically induced JNK network architecture to tackle breast cancer chemoresistance
    The current generation of cancer therapies mostly target components of signalling pathways, being either small molecule inhibitors or monoclonal antibodies to cell surface receptors. It is fas...
      Breast Cancer
      Chemo resistance
  • T1,T2
    David Thomas: Molecular Screening and Therapeutics Program (MOST)
    The rapid advance in genomic technologies presents the unprecedented opportunity to molecularly phenotype cancers and link genetic information to therapeutic opportunities for individual patie...
      Genetics/genomics
      Personalised medicine
      New therapies and diagnostics
  • T2,T3
    Erin Moth: Understanding and optimising chemotherapy decision-making for older adults with cancer
    Geriatric oncology is an emerging subspecialty of oncology, developed in response to the ageing population. This research has broad application to clinical practice given the median age at dia...
      Psychosocial
  • T1
    Fast Linear Laser Scanning Technology: The ZEISS LSM 800 Confocal Microscope for the Open Access, Bosch Institute Advanced Microscopy Facility
    Funding was awarded for revolutionary technology, the ZEISS LSM 800 confocal microscope with Airyscan, for the Open-Access, Multi-User Bosch Institute Advanced Microscopy Facility (AMF) at the Uni...
      CINSW Research Equipment Grant
  • T1
    Hayley Suen & team: Restoring the Function of Clonal Cytotoxic T cells in Multiple Myeloma to Develop Novel Therapies and Define the Antigenic Landscape
    Multiple myeloma is an incurable disease so new treatments are required to provide a cure for patients. An attractive form of treatment is the use of a patient's own T cells to fight their can...
      Immunotherapy
      New therapies and diagnostics
      Myeloma
  • T1
    Helen McGuire: Development of a novel test to predict clinical response to checkpoint therapy in lung cancer and mesothelioma
    Immune checkpoint inhibitor therapy has provided new hope to cancer patients whose tumours have resisted conventional therapy. One of the most recent success stories has been effective treatmen...
      Immunotherapy
      New therapies and diagnostics
      Lung cancer
      Mesothelioma
  • T1
    Jeff Holst & team: Targeting glutamine metabolism to starve triple-negative breast cancer
    Jeff's team are studying nutrient pumps that bring the amino acid glutamine into cancer cells. They have discovered that these pumps are increased in triple-negative breast cancer, a subset tha...
      Cancer metabolism
      New therapies and diagnostics
      Breast Cancer
  • T2,T3
    Jessica Lee & team: Multidisciplinary Management Of Episodic Breathlessness In Adults With Advanced Cancer - a mixed methods pilot study of a complex intervention
    This T2 project involves development and evaluation of a complex intervention to improve episodic breathlessness in adults with advanced cancer. This intervention will comprise a patient held epis...
      Clinical Trials
  • T2
    John Simes: MDT scoping project
    The aim of this research was to describe the multi-disciplinary teams (MDTs) in our consortium and to share findings with survey participants to provide them an opportunity to learn more abou...
      MDT
  • T2
    Jolyn Hersch: Supporting informed choice for management of screen-detected Ductal Carcinoma in Situ (DCIS) among older women (70 years and over)
    Breast screening often finds ductal carcinoma in situ (DCIS) - cell changes which may or may not become cancer later on. Treatments for DCIS (surgery, radiation and drugs) have harmful side ef...
      Psychosocial
      Breast Cancer
  • T1,T2
    Julius Kim & team: Systematic effects of Gioblastoma multiforme (GBM) and GBM-released extracellular vesicles on immune suppression
    Despite recent improvements in cancer therapies, the median survival for patients with brain tumours is only 15 months. We need to urgently develop better treatment options. Anti-tumour vaccin...
      Dendritic cell
  • T2
    Kate White & team: The financial impact of cancer treatment on Australian patients and families
    It is recognised that individuals and their families experience financial costs associated with the diagnosis of cancer and subsequent treatment.  Little attention has been paid to identi...
      Psychosocial
      Cancer costs
  • T1
    LC-PLAT - Lung Cancer Cohort - a Platform to Study Serial Biospecimens and Matched Clinical Data
    The project aimed to optimise a platform for the collection of serial lung cancer tissue and blood biospecimens for research during routine clinical practice. Prospective biobanking and collection...
      Lung cancer
      Biobanking
  • T2,T3
    Liesbeth Geerligs: Evaluating the implementation of a clinical pathway for managing anxiety and depression in cancer patients into clinical care and policy
    Anxiety and depression are more highly prevalent in cancer patients. Evidenc ebased pathways are required to ensure that patients receive appropriate care. Effective strategies to implement such p...
      Psychology
      Evidence-based practice
      Implementation research
  • T1
    Lorraine Chantrill and team: IMPACT Trial
    Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) aimed to improve outcomes for patients with advanced pancreas cancer by using molecular analysis of tumor tissue to guide treatment ...
      Personalised medicine
      Clinical Trials
      Pancreatic cancer
      Treatment
  • T1
    Magdalena Budzinska: Discovering Novel Non-Invasive Diagnostic and Prognostic Markers in Hepatocellular Carcinoma
    Magdalena's research addresses the urgent need in HCC management for markers that predict HCC propensity and behaviour. It has the potential to be translated into clinical practice at the level...
      Biomarkers
      New therapies and diagnostics
  • T1
    Mark Larance: Nutrient Deprivation and the Protective Proteome for the Prevention of Disease
    Cancer is a major cause of illness and death in Australia. Key risk factors for colorectal cancer and many other cancer types are poor diet, obesity and age. In animals, short periods of nutrient ...
      Cancer metabolism
      Colorectal cancer
      Proteomics
  • T2,T3
    Mohsen Shafiei: Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer
    The aim of this research project is to determine and compare and pharmacokinetics (PK) of capecitabine and its metabolites in older and younger adults with cancer, and the correlation between ...
      Prospective observational study
      Drug development
      Treatment
  • T2,T3
    Nicola Lawrence: Optimising cooperative group cancer clinical trials in the era of molecularly targeted treatments
    The discovery and rapid development of multiple targeted therapies for malignant diseases has begun a new era of optimism in cancer drug development. These advances require a reappraisal of clinic...
      Medical oncology
      Clinical Trials
  • T2
    Nicole Rankin and Team: Sydney Catalyst Member Experience Survey
    The aim of this research was to qualitatively explore the experiences of members of Sydney Catalyst to identify members' understanding and perceptions of translational research, benefits of me...
      Member Experience
  • T2,T3
    Nicole Rankin and Team: T3 Lung Cancer Flagship Program, Defining Knowledge Translation in Cancer
    The project was completed in three stages. The first stage, the team identified evidence-practice gaps in lung cancer through a scoping review and engaged clinicians from three multidiscipli...
      Intervention
      Evidence into practice
      Integrated research in quality care
      Evidence-based practice
      Implementation research
      Lung cancer
  • T2,T3
    Peey Sei Kok: What are good surrogates for clinically meaningful benefit of new oncology therapies in advanced cancers?
    Robust surrogate endpoints have the potential to reduce the clinical, economic and time burden associated with conducting RCTs and drug development. Our work will feed into future collaborative...
      Phase i/ii clinical trial
      Phase iii clinical trial
      Drug development
      Clinical Trials
  • T1,T2
    Peter Luk & team: Understanding the Body's Response to Cancer Invasion and Progression
      Cutaneous squamous cell carcinoma (cSCC; skin cancer) is the most common human cancer with the potential to spread to other parts of the body. Australia has the highest rate of cSCC i...
      Head and Neck Cancer
  • T1
    Philip Hogg: ACRF Centenary Cancer Research Centre
    The goal of the ACRF Centenary Cancer Research Centre is to understand the link between diet, metabolism and tumour initiation and development at a molecular level, and to design new therapies usi...
      Cancer metabolism
      New therapies and diagnostics
  • T1,T2
    Philip Hogg: Measure of thrombotic risk in cancer patients
    Thrombotic events are a major cause of death in cancer patients and are associated with worsened short‐term and long‐term survival. Prof Hogg and his team developed a new diagnostic test for ...
      Thrombosis
  • T2,T3
    Phyllis Butow & team: Anxiety and Depression Pathway Program
    Anxiety and depression are common in those diagnosed with cancer, causing suffering to individuals and their families and potentially increasing health services usage and decreasing adherence ...
      Psychosocial
      Psychology
      Evidence-based practice
      Clinical Trials
      Anxiety
      Depression
  • T1
    Roger Bourne & team: Gold-standard assessment of prostate cancer MRI accuracy
    A recent health economics analysis identified doctors' lack of confidence in prostate MRI as a major inhibitor to increased choice of active surveillance for low risk prostate cancer. Furthermore,...
      Imaging
      Urogenital
      Prostate
      MRI
  • T2,T3
    Sara Wahlroos: The Effect of Exercise in combination with chemotherapy on breast cancer tumour biology, immunology and vascularisation - a non-pharmaceutical approach to current oncology treatment?
    In this study, Sara will examine the effect of exercise in mice with different breast cancer subtypes, to assess whether exercise has an additional effect in reducing tumour growth when combine...
      Breast Cancer
      Treatment
  • T1
    Sarah Sutherland: Novel targets for a new generation of therapeutic cancer vaccines
    DC vaccines are well tolerated and can induce an anti- tumour immune response. Current vaccine strategies use in vitro generated "DC" which are loaded with antigen, stimulated and transfused back ...
      Dendritic cell
      Immunotherapy
      Urogenital
  • T1
    Sonia Yip: Biobanking - Patient and healthcare Professional Attitudes and Experiences of universal consent (B-PPAE)
    The Biobanking Qualitative Evaluation Project was initially developed to explore patient and health professional views of universal consent for biobanking procedures. It was later expanded to canv...
      Lung cancer
      Biobanking
      Consent
  • T1,T2,T3
    Sydney Catalyst Scholarships Awarded pre July 2016
    We aim to encourage training and development of outstanding researchers and clinicians from within Sydney Catalyst units, who have the potential to develop highly significant ca...
      Scholarships
  • T1
    The Next Wave of Cancer Genomics: Resolving Complex Structural Variants and Tumour Heterogeneity with Linked Short-Read
    Large genomic structural rearrangements are just important as short mutations in cancer pathogenesis. However, these critical events are often missed by conventional sequencing technologies. The f...
      CINSW Research Equipment Grant
  • T1
    Thomas Cox: Biomechanical priming of organotropism in metastasising breast cancer cells
    Breast cancer is the most common cancer in women worldwide. It is estimated that more than 1.7 million new cases of breast cancer occurred among women worldwide in 2012. We already know that ti...
      Breast Cancer
      Tissue stiffness
      Metastasis
  • T1
    Thomas Johnson: YB-1: A central player in the carcinogenesis and malignant behaviour of malignant pleural mesothelioma
    Malignant pleural mesothelioma (MPM) is an aggressive, asbestos-induced malignancy that responds poorly to treatment. The combination of cisplatin and pemetrexed, which is the current standard...
      Biomarkers
      Mesothelioma